Published in Can J Biochem on October 01, 1966
Microbial oxidation of amines. Spectral and kinetic properties of the primary amine dehydrogenase of Pseudomonas AM1. Biochem J (1971) 1.09
The kinetics of phenethylhydrazine oxidation by monoamine oxidase. Biochem J (1971) 0.93
maoB, a gene that encodes a positive regulator of the monoamine oxidase gene (maoA) in Escherichia coli. J Bacteriol (1996) 0.91
Further properties of multiple forms of mitochondrial monoamine oxidase. Biochem J (1969) 0.87
Inhibition of monoamine oxidase by substituted hydrazines. Biochem J (1972) 0.78
Proceedings: Reduction of platelet monoamine oxidase activity in iron deficiency anaemia. Br J Pharmacol (1974) 0.75
Proceedings: Monoamine oxidase active site; the binding to and titration of monoamine oxidase with (14C)-selective inhibitors. Br J Pharmacol (1976) 0.75
Proceedings: Some studies on the purification of monoamine oxidase by affinity chromatography. Br J Pharmacol (1975) 0.75
Rat liver mitochondrial monoamine oxidase, a flavin-containing enzyme. Biochem J (1971) 0.75
A phenylethylamine oxidising defect in migraine. Nature (1974) 2.28
Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain. J Neural Transm (1988) 2.10
Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem (1989) 1.94
Conjugation defect in tyramine-sensitive migraine. Nature (1971) 1.91
Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: a longterm study. J Neural Transm (1985) 1.89
Multiple forms of rat brain monoamine oxidase. Nature (1969) 1.77
Striatal amines, experimental tremor and the effect of harmaline in the monkey. Brain (1966) 1.76
Selective increase of iron in substantia nigra zona compacta of parkinsonian brains. J Neurochem (1991) 1.70
Multiple forms of human brain mitochondrial monoamine oxidase. Nature (1970) 1.69
Deprenyl in Parkinson's disease. Lancet (1977) 1.66
The potentiation of the anti akinetic effect after L-dopa treatment by an inhibitor of MAO-B, Deprenil. J Neural Transm (1975) 1.62
Multiple forms of monoamine oxidase: functional significance. Pharmacol Rev (1972) 1.56
Brain iron pathways and their relevance to Parkinson's disease. J Neurochem (2001) 1.55
Altered brain metabolism of iron as a cause of neurodegenerative diseases? J Neurochem (1994) 1.46
Implications of combined treatment with 'Madopar' and L-deprenil in Parkinson's disease. A long-term study. Lancet (1977) 1.38
Effects of monoamine oxidase inhibition by clorgyline, deprenil or tranylcypromine on 5-hydroxytryptamine concentrations in rat brain and hyperactivity following subsequent tryptophan administration. Br J Pharmacol (1975) 1.38
Quipazine: its effects on rat brain 5-hydroxytryptamine metabolism, monoamine oxidase activity and behaviour. Neuropharmacology (1976) 1.35
Oxidative stress: free radical production in neural degeneration. Pharmacol Ther (1994) 1.33
Green tea polyphenol (-)-epigallocatechin-3-gallate prevents N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurodegeneration. J Neurochem (2001) 1.30
Monoamine metabolites in lumbar CSF: the question of their origin in relation to clinical studies. Brain Res (1974) 1.29
Brain iron and ferritin in Parkinson's and Alzheimer's diseases. J Neural Transm Park Dis Dement Sect (1990) 1.27
Iron- and riboflavin-dependent metabolism of a monamine in the rat in vivo. Science (1971) 1.25
Effect of iron chelators on dopamine D2 receptors. J Neurochem (1985) 1.22
A new method to measure brain serotonin synthesis in vivo. I. Theory and basic data for a biological model. J Cereb Blood Flow Metab (1990) 1.20
Promotion of 4-hydroxy-3-methoxyphenylglycol formation in man by reserpine. Nature (1968) 1.19
Transport of L-tryptophan into slices of rat cerebral cortex. J Neurochem (1972) 1.17
Mechanism of 6-hydroxydopamine neurotoxicity. J Neural Transm Suppl (1997) 1.16
MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease. Eur J Pharmacol (1991) 1.13
Endothelial cells from bovine adrenal medulla develop capillary-like growth patterns in culture. Proc Natl Acad Sci U S A (1985) 1.11
Inhibition of mitochondrial complexes I and IV by 6-hydroxydopamine. Eur J Pharmacol (1995) 1.11
Unaltered aconitase activity, but decreased complex I activity in substantia nigra pars compacta of patients with Parkinson's disease. Neurosci Lett (1994) 1.10
Evidence for dopamine deamination by both type A and type B monoamine oxidase in rat brain in vivo and for the degree of inhibition of enzyme necessary for increased functional activity of dopamine and 5-hydroxytryptamine. Br J Pharmacol (1977) 1.10
Human brain monoamine oxidase: multiple forms and selective inhibitors. Nature (1972) 1.09
The binding of (14C)phenethylhydrazine to rat liver monoamine oxidase. Biochem Pharmacol (1975) 1.08
The metabolism of 5-hydroxytryptamine and beta-phenylethylamine in perfused rat lung and in vitro. Br J Pharmacol (1979) 1.07
Physicochemical properties, development, and regulation of central and peripheral monoamine oxidase activity. Adv Biochem Psychopharmacol (1974) 1.07
Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo. J Neurochem (1996) 1.07
Antidepressant action of tryptophan. Lancet (1974) 1.05
On the mode of action of L-deprenyl in the human central nervous system. J Neural Transm (1978) 1.05
Dopa decarboxylase: substrates, coenzyme, inhibitors. Pharmacol Rev (1966) 1.04
Iron-melanin complex in substantia nigra of parkinsonian brains: an x-ray microanalysis. J Neurochem (1992) 1.04
The iron chelator desferrioxamine (Desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons. J Neurochem (1991) 1.04
Decreased monoamine oxidase activity in liver of iron-deficient rats. Can J Biochem (1969) 1.03
Properties of the monoamine oxidase of rat liver mitochondria. Adv Pharmacol (1968) 1.02
Gene expression analysis in N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice model of Parkinson's disease using cDNA microarray: effect of R-apomorphine. J Neurochem (2001) 1.01
Heterogeneity of rat brain mitochondrial monoamine oxidase. Adv Biochem Psychopharmacol (1974) 1.00
Decrease of cerebral serotonin and 5-hydroxyindolylacetic acid caused by (-)-alpha-methyltryptophan. J Neurochem (1970) 1.00
Serotonin synthesis rate measured in living dog brain by positron emission tomography. J Neurochem (1991) 0.99
Homovanillic acid and dihydroxyphenylacetic acid in the striatum of monkeys with brain lesions. Can J Physiol Pharmacol (1967) 0.99
Tyramine antagonistic properties of AGN 1135, an irreversible inhibitor of monoamine oxidase type B. Br J Pharmacol (1981) 0.99
The oestrous cycle and monoamine oxidase activity. Br J Pharmacol (1973) 0.99
Reversible effect of L-dopa on tremor and catatonia induced by alpha-methyl-p-tyrosine. Can J Physiol Pharmacol (1970) 0.99
Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with l-deprenyl. J Neurochem (1986) 0.98
Tranylcypromine ('Parnate') overdose: measurement of tranylcypromine concentrations and MAO inhibitory activity and identification of amphetamines in plasma. Psychol Med (1979) 0.98
Brain iron: a lesson from animal models. Am J Clin Nutr (1989) 0.98
The effect of copper loading on the distribution of copper in rat liver cytosol. Biochem Med (1973) 0.98
Tryptophan catabolism by tryptophan pyrrolase in rat liver. The effect of tryptophan loads and changes in tryptophan pyrrolase activity. J Biol Chem (1975) 0.98
Iron-melanin interaction and lipid peroxidation: implications for Parkinson's disease. J Neurochem (1991) 0.98
Effects of aporphine and emetine alkaloids on central dopaminergic mechanisms in rats. Eur J Pharmacol (1972) 0.98
Determination of UDPG and UDPGA in tissues. Anal Biochem (1967) 0.97
Sites of origin in the central nervous system of monoamine metabolites measured in human cerebrospinal fluid. J Neurol Neurosurg Psychiatry (1973) 0.97
Liver and brain tryptophan metabolism following hydrocortisone administration to rats and gerbils. Br J Pharmacol (1975) 0.97
The Biochemistry of Mental Disease. Can Med Assoc J (1961) 0.97
The distal axis of growth hormone (GH) in nutritional disorders: GH-binding protein, insulin-like growth factor-I (IGF-I), and IGF-I receptors in obesity and anorexia nervosa. Metabolism (1992) 0.97
Selective acetylenic 'suicide' and reversible inhibitors of monoamine oxidase types A and B. Br J Pharmacol (1981) 0.96
Nutritional iron and dopamine binding sites in the rat brain. Pharmacol Biochem Behav (1982) 0.96
Importance of tryptophan pyrrolase and aromatic amino acid decarboxylase in the catabolism of tryptophan. Biochem Pharmacol (1978) 0.96
Proceedings: Substrate and strain-dependent differences in the development of monoamine oxidase in the rat brain. Br J Pharmacol (1975) 0.96
Alpha-methyltryptophan: effects on synthesis and degradation of serotonin in the brain. Neuropharmacology (1972) 0.95
Dopamine, 6-hydroxydopamine, iron, and dioxygen--their mutual interactions and possible implication in the development of Parkinson's disease. Biochim Biophys Acta (1996) 0.95
Metabolism of phenylethylamine in rat isolated perfused lung: evidence for monoamine oxidase 'type B' in lung. Br J Pharmacol (1976) 0.94
Correlative neuroanatomical and neuropharmacological study of tremor and catatonia in the monkey. Neuropharmacology (1971) 0.94
Serotonin and dopamine in the extrapyramidal system. Adv Pharmacol (1968) 0.94
Effect of apomorphine on growth hormone, prolactin, luteinizing hormone and follicle-stimulating hormone levels in human serum. J Clin Endocrinol Metab (1973) 0.94
Nature of inhibition of mitochondrial respiratory complex I by 6-Hydroxydopamine. J Neurochem (1996) 0.93
Neuroprotective strategies in Parkinson's disease using the models of 6-hydroxydopamine and MPTP. Ann N Y Acad Sci (2000) 0.93
The effect of yohimbine on brain serotonin metabolism, motor behavior and body temperature of the rat. Eur J Pharmacol (1971) 0.93
Intranigral iron injection induces behavioral and biochemical "parkinsonism" in rats. J Neurochem (1991) 0.93
Tryptophan and 5-hydroxyindoleacetic acid in human cerebrospinal fluid. J Neurochem (1974) 0.92
Mössbauer spectroscopic studies of purified human neuromelanin isolated from the substantia nigra. J Neurochem (1995) 0.92
5-Hydroxytryptamine release in vivo from a cytoplasmic pool: studies on the 5-HT behavioural syndrome in reserpinized rats. Br J Pharmacol (1985) 0.92
The influence of tissue environment on the rates of metabolic processes and the properties of enzymes. Biochem Pharmacol (1975) 0.92
Impaired iron homeostasis in Parkinson's disease. J Neural Transm Suppl (2000) 0.91
Alpha-methyltryptophan and its actions on tryptophan metabolism. Fed Proc (1971) 0.91
A new method to measure brain serotonin synthesis in vivo. II. A practical autoradiographic method tested in normal and lithium-treated rats. J Cereb Blood Flow Metab (1990) 0.91
Localization of MAO-A and MAO-B in human brain: a step in understanding the therapeutic action of L-deprenyl. Adv Neurol (1987) 0.91
Neurochemical bases of tremor and other disorders of movement. Can Med Assoc J (1966) 0.91
Tryptophan-nicotinamide, imipramine and their combination in depression. A controlled study. Acta Psychiatr Scand (1979) 0.91
MPTP and 6-hydroxydopamine-induced neurodegeneration as models for Parkinson's disease: neuroprotective strategies. J Neurol (2000) 0.90
Formation of respiratory 14CO2 from variously labeled forms of tryptophan-14C in intact and adrenalectomized rats. Arch Biochem Biophys (1968) 0.90
Pharmacology of selegiline. Neurology (1996) 0.90
Long-term consequence of early iron-deficiency on dopaminergic neurotransmission in rats. Int J Dev Neurosci (1986) 0.89
Chemical evidence for 6-hydroxydopamine to be an endogenous toxic factor in the pathogenesis of Parkinson's disease. J Neural Transm Suppl (1995) 0.89
Iron and ferritin in substantia nigra in Parkinson's disease. Adv Neurol (1993) 0.89
Relationship between rat brain and cisternal CSF tryptophan concentrations. J Neurol Neurosurg Psychiatry (1976) 0.89
Use of cerebrospinal fluid drawn at pneumoencephalography in the study of monoamine metabolism in man. J Neurol Neurosurg Psychiatry (1974) 0.89
Pharmacology of rasagiline (N-propargyl-1R-aminoindan). Adv Neurol (1999) 0.89